Literature DB >> 18453624

Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun.

Daejin Kim1, Talia Hoory, Archana Monie, Jenny Pan-Yun Ting, Chien-Fu Hung, T-C Wu.   

Abstract

Administration of DNA vaccines via gene gun has emerged as an important form of Ag-specific immunotherapy. The MHC CIITA is a master regulator of MHC class II expression and also induces expression of class I molecules. We reasoned that the gene gun administration of CIITA DNA with DNA vaccines employing different strategies to improve MHC I and II processing could enhance DNA vaccine potency. We observed that DC-1 cells transfected with CIITA DNA lead to higher expression of MHC I and II molecules, leading to enhanced Ag presentation through the MHC I/II pathways. Furthermore, our data suggested that coadministration of DNA-encoding calreticulin (CRT) linked to human papillomavirus (HPV) 16 E6 Ag (CRT/E6) with CIITA DNA leads to enhanced E6-specific CD8(+) T cell immune responses in vaccinated mice. In addition, coadministration of the combination of CRT/E6 DNA with CIITA DNA and DNA encoding the invariant chain (Ii) linked to the pan HLA-DR-reactive epitope (Ii-PADRE) further enhanced E6-specific CD8(+) T cell immune responses in vaccinated mice. Treatment with the combination vaccine was also shown to enhance the antitumor effects and to prolong survival in TC-1 tumor-bearing mice. Vaccination with the combination vaccine also led to enhanced E6-specific CD8(+) memory T cells and to long-term protection against TC-1 tumors and prolonged survival in vaccinated mice. Thus, our findings suggest that the combination of CIITA DNA with CRT/E6 and Ii-PADRE DNA vaccines represents a potentially effective means to combat tumors in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18453624      PMCID: PMC2872557          DOI: 10.4049/jimmunol.180.10.7019

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

Review 1.  Modifying professional antigen-presenting cells to enhance DNA vaccine potency.

Authors:  Chien-Fu Hung; Mu Yang; T C Wu
Journal:  Methods Mol Med       Date:  2006

2.  DNA-based immunization by in vivo transfection of dendritic cells.

Authors:  C Condon; S C Watkins; C M Celluzzi; K Thompson; L D Falo
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

3.  Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.

Authors:  T D Armstrong; V K Clements; B K Martin; J P Ting; S Ostrand-Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

4.  Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides.

Authors:  J Alexander; J Sidney; S Southwood; J Ruppert; C Oseroff; A Maewal; K Snoke; H M Serra; R T Kubo; A Sette
Journal:  Immunity       Date:  1994-12       Impact factor: 31.745

5.  Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP.

Authors:  B Sadasivan; P J Lehner; B Ortmann; T Spies; P Cresswell
Journal:  Immunity       Date:  1996-08       Impact factor: 31.745

6.  Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6.

Authors:  Tae Woo Kim; Chien-Fu Hung; David A K Boyd; Liangmei He; Cheng-Tao Lin; Dion Kaiserman; Phillip I Bird; T-C Wu
Journal:  Cancer Res       Date:  2004-01-01       Impact factor: 12.701

7.  Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.

Authors:  Shiwen Peng; Hongxiu Ji; Cornelia Trimble; Liangmei He; Ya-Chea Tsai; Jessica Yeatermeyer; David A K Boyd; Chien-Fu Hung; T-C Wu
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.

Authors:  K Y Lin; F G Guarnieri; K F Staveley-O'Carroll; H I Levitsky; J T August; D M Pardoll; T C Wu
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

Review 9.  Calreticulin: not just another calcium-binding protein.

Authors:  P D Nash; M Opas; M Michalak
Journal:  Mol Cell Biochem       Date:  1994-06-15       Impact factor: 3.396

10.  Serine residues 286, 288, and 293 within the CIITA: a mechanism for down-regulating CIITA activity through phosphorylation.

Authors:  Susanna F Greer; Jonathan A Harton; Michael W Linhoff; Christin A Janczak; Jenny P-Y Ting; Drew E Cressman
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

View more
  14 in total

1.  Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.

Authors:  Max A Cheng; Emily Farmer; Claire Huang; John Lin; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2018-03-16       Impact factor: 5.695

2.  The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence.

Authors:  Emeline Ragonnaud; Peter Holst
Journal:  Ther Adv Vaccines       Date:  2013-05

Review 3.  Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines.

Authors:  Andrea Orsi; Filippo Ansaldi; Daniela de Florentiis; Antonella Ceravolo; Valentina Parodi; Paola Canepa; Martina Coppelli; Giancarlo Icardi; Paolo Durando
Journal:  Hum Vaccin Immunother       Date:  2013-01-07       Impact factor: 3.452

4.  Advances in Gene Delivery Systems.

Authors:  Kenya Kamimura; Takeshi Suda; Guisheng Zhang; Dexi Liu
Journal:  Pharmaceut Med       Date:  2011-10-01

5.  DNA vaccines for cervical cancer.

Authors:  Chien-Fu Huang; Archana Monie; Wei-Hung Weng; Tc Wu
Journal:  Am J Transl Res       Date:  2010-01-02       Impact factor: 4.060

6.  Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen.

Authors:  Thomas H Shin; Panyupa Pankhong; Jian Yan; Amir S Khan; Niranjan Y Sardesai; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2012-02-16       Impact factor: 3.452

Review 7.  TAA polyepitope DNA-based vaccines: a potential tool for cancer therapy.

Authors:  Roberto Bei; Antonio Scardino
Journal:  J Biomed Biotechnol       Date:  2010-06-17

Review 8.  Physical approaches for nucleic acid delivery to liver.

Authors:  Kenya Kamimura; Dexi Liu
Journal:  AAPS J       Date:  2008-12-13       Impact factor: 4.009

Review 9.  The future of human DNA vaccines.

Authors:  Lei Li; Fadi Saade; Nikolai Petrovsky
Journal:  J Biotechnol       Date:  2012-09-07       Impact factor: 3.307

Review 10.  Therapeutic HPV DNA vaccines.

Authors:  Ken Lin; Elena Roosinovich; Barbara Ma; Chien-Fu Hung; T-C Wu
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.